Hyaluronidase

Summary

Hyaluronidase (CHEMBL1201636) is an approved enzyme (ATC B06AA03); indicated across 26 conditions including myocardial infarction and myocardial ischemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: B06AA03
• Indications: 26 conditions
• Clinical trials: 28

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201636
Name	Hyaluronidase
Type	Enzyme
Max phase	4
ATC	B06AA03

Also known as: Hialuronidasa, Hyaluronidase, Hyaluronidase (bovine), Hyaluronidase bovine, bovine, Hyaluronidases, Hyaluronoglucosaminidase, Hyalase, Jalovis, HYALURONIDASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

21 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
myocardial infarction	3	MONDO:0005068	EFO:0000612
myocardial ischemia	3	MONDO:0024644	EFO:1001375
frozen shoulder	3	MONDO:0006763	EFO:1000941
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
follicular lymphoma	3	MONDO:0018906	MONDO:0018906
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
lymphoma	3	MONDO:0005062	EFO:0000574
coronary artery disorder	3	MONDO:0005010	EFO:0001645
hereditary amyloidosis	3	MONDO:0018634	MONDO:0019438
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
T-cell acute lymphoblastic leukemia	2	MONDO:0004963	EFO:0000209
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
breast neoplasm	2	MONDO:0021100	MONDO:0007254
prostate carcinoma	2	MONDO:0005159	EFO:0001663
neoplasm	2	MONDO:0005070	MONDO:0004992
melanoma	2	MONDO:0005105	EFO:0000756
non-autoimmune hemolytic anemia	1	MONDO:0021559	EFO:0005558
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147
allergic disease	1	MONDO:0005271	MONDO:0005271

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 28.

Phase distribution

Phase	Trials
Not specified	11
EARLY_PHASE1	6
PHASE3	3
PHASE2	3
PHASE4	2
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01719978	PHASE4	COMPLETED	Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics
NCT03243500	PHASE4	COMPLETED	Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery
NCT07000058	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Wide-Awake Local Anesthesia No Tourniquet (WALANT) With Versus Without Hyaluronidase for Hand Surgery
NCT00000493	PHASE3	COMPLETED	Multicenter Investigation of Limitation of Infarct Size (MILIS)
NCT04347733	PHASE3	COMPLETED	Hyaluronidase in Intra-articular Steroid Injection Treating the Adhesive Capsulitis for Shoulder
NCT05083663	PHASE2/PHASE3	UNKNOWN	Effectiveness of Adding Hyaluronidase to Bupivacaine in Ultrasound Guided Supraclavicular Brachial Plexus Block
NCT06604546	PHASE3	COMPLETED	Hyaluronidase Assisted Subcutaneous Infusion
NCT03306615	PHASE2	ACTIVE_NOT_RECRUITING	Peripheral Modulation of Muscle Stiffness and Spasticity
NCT01689363	PHASE2	COMPLETED	Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
NCT05498220	PHASE2	TERMINATED	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02199028	PHASE1	COMPLETED	Hyaluronidase Effect on Infusion Set Life
NCT01722916	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
NCT06839391	EARLY_PHASE1	NOT_YET_RECRUITING	Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS
NCT01945099	EARLY_PHASE1	COMPLETED	Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
NCT03411330	EARLY_PHASE1	COMPLETED	Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study
NCT05344495	EARLY_PHASE1	UNKNOWN	Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome:
NCT05995626	EARLY_PHASE1	COMPLETED	Hyaluronidase Via LADD Scleroderma-induced Microstomia
NCT07141589	Not specified	RECRUITING	Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries
NCT07269613	Not specified	NOT_YET_RECRUITING	Pulsed Radiofrequency Versus Hyaluronidase Hydrodissection for Treatment of Carpal Tunnel Syndrome
NCT07298746	Not specified	NOT_YET_RECRUITING	Oct Angiography Changes After Local Anesthesia in Cataract Surgery
NCT02059694	Not specified	WITHDRAWN	Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid’s Surgery
NCT03266406	Not specified	UNKNOWN	Effect of Hyaluronidase on Intraocular Pressure
NCT03436836	Not specified	COMPLETED	Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery
NCT03660020	Not specified	UNKNOWN	Ultrasound Guided Erector Spinae Plane Block in Breast Surgery
NCT03675295	Not specified	COMPLETED	Efficacy of Hyalase Hydro-dissection in Treatment of Carpal Tunnel: Randomized Double Blind Controlled Clinical Trial
NCT05280223	Not specified	COMPLETED	Dexmedetomidine Versus Hyalase Treatment of Carpal Tunnel Syndrome
NCT05671172	Not specified	COMPLETED	Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section
NCT07436546	Not specified	COMPLETED	Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).